Cat. No.: HY-15531

Venetoclax

(Synonyms: ABT-199; GDC-0199; RG7601)

246 Cited Publications

Customer Review

Based on 246 publication(s) in Google Scholar

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a K_i of less than 0.01 nM. Venetoclax induces autophagy.

For research use only. We do not sell to patients.

Purity: 99.95%
CAS No.: 1257044-40-8
Formula: C₄₅H₅₀ClN₇O₇S
Molecular Weight:868.44

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Venetoclax Chemical Structure

CAS No.: 1257044-40-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (246)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a K_i of less than 0.01 nM. Venetoclax induces autophagy^[1]^[2]^[3].

IC₅₀ & Target^[1]

Bcl-2

0.01 nM (Ki)

Bcl-xL

48 nM (Ki)

Bcl-W

245 nM (Ki)

All Bcl-2 Family Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	1.5 μM Compound: ABT-199	Cytotoxicity against human A549 cells assessed as inhibition of cell growth Cytotoxicity against human A549 cells assessed as inhibition of cell growth	[PMID: 38909705]
Cancer cell lines	GI₅₀	2.6 μM Compound: ABT-199	Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	2.7 μM Compound: ABT-199	Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	2.77 μM Compound: ABT-199	Cytotoxicity against human breast cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human breast cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	2.85 μM Compound: ABT-199	Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	3.33 μM Compound: ABT-199	Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	3.35 μM Compound: ABT-199	Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	3.51 μM Compound: ABT-199	Cytotoxicity against human prostate cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human prostate cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
DMS-79	EC₅₀	4.62 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human DMS 79 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human DMS 79 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
EOL1	EC₅₀	0.1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human EOL1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human EOL1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
GDM-1	EC₅₀	0.1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human GDM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human GDM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
HEK-293T	IC₅₀	>20 μM Compound: ABT-199	Cytotoxicity against HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 34228434]
HEL	EC₅₀	3.37 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human HEL harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human HEL harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
HeLa	IC₅₀	>20 μM Compound: ABT-199	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34228434]
HL-60	EC₅₀	0.1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human HL-60 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human HL-60 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
HL-60	EC₅₀	8.1 μM Compound: ABT-199	Induction of apoptosis in human HL-60 cells measured after 48 hrs by FITC-Annexin V/PS staining based Induction of apoptosis in human HL-60 cells measured after 48 hrs by FITC-Annexin V/PS staining based	[PMID: 33197310]
HL-60	IC₅₀	0.077 μM Compound: ABT-199	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34228434]
K562	EC₅₀	2.1 μM Compound: ABT199	Cytotoxicity against human K562 cells assessed as cell survival measured after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell survival measured after 72 hrs by MTT assay	[PMID: 34216984]
Kasumi 1	EC₅₀	1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human Kasumi 1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human Kasumi 1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
KG-1	EC₅₀	0.85 μM Compound: ABT-199	Induction of apoptosis in human KG-1 cells measured after 48 hrs by FITC-Annexin V/PS staining based Induction of apoptosis in human KG-1 cells measured after 48 hrs by FITC-Annexin V/PS staining based	[PMID: 33197310]
KG-1	EC₅₀	1.2 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human KG-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human KG-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
Leukemia cell	GI₅₀	2.11 μM Compound: ABT-199	Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
MCF7	EC₅₀	1.35 μM Compound: ABT-199	Induction of apoptosis in human MCF7 cells measured after 48 hrs by FITC-Annexin V/PS staining based Induction of apoptosis in human MCF7 cells measured after 48 hrs by FITC-Annexin V/PS staining based	[PMID: 33197310]
Melanoma cell	GI₅₀	1.75 μM Compound: ABT-199	Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
ML-2	EC₅₀	0.1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human ML-2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human ML-2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MOLM-13	EC₅₀	0.1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human MOLM-13 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human MOLM-13 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MOLM-16	EC₅₀	0.04 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human MOLM16 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human MOLM16 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MOLT-4	EC₅₀	>5000 nM Compound: 23	Antiproliferative activity against human MOLT4 cells in presence of 10% human serum Antiproliferative activity against human MOLT4 cells in presence of 10% human serum	[PMID: 28926247]
MOLT-4	EC₅₀	>5000 nM Compound: ABT-199, GDC-0199	Antiproliferative activity against Bcl-xl dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay Antiproliferative activity against Bcl-xl dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay	[PMID: 25787766]
MOLT-4	EC₅₀	8 nM Compound: ABT-199, GDC-0199	Antiproliferative activity against Bcl-2 dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay Antiproliferative activity against Bcl-2 dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay	[PMID: 25787766]
MOLT-4	IC₅₀	2823 nM Compound: 1c; ABT-199	Inhibition of cell growth in human MOLT-4 cells incubated for 2 days by CellTiter-Glo luminescent cell viability assay Inhibition of cell growth in human MOLT-4 cells incubated for 2 days by CellTiter-Glo luminescent cell viability assay	[PMID: 38695063]
MV4-11	EC₅₀	0.1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human MV4-11 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human MV4-11 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MV4-11	IC₅₀	0.44 μM Compound: 7; ABT199	Antiproliferative activity against human MV4-11 cells expressing high BCL-2 assessed as cell viability measured after 72 hrs by Cell Counting Kit-8 assay Antiproliferative activity against human MV4-11 cells expressing high BCL-2 assessed as cell viability measured after 72 hrs by Cell Counting Kit-8 assay	[PMID: 38913996]
NCI-H1048	EC₅₀	2.7 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NCI-H1048 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H1048 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H1417	EC₅₀	4.1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NCI-H1417 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H1417 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H1836	EC₅₀	5 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NCI-H1836 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H1836 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H187	EC₅₀	0.85 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NCI-H187 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H187 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H211	EC₅₀	0.33 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NCI-H211 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H211 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H345	EC₅₀	1.2 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NCI-H345 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H345 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H446	EC₅₀	2.4 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NCI-H446 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H446 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H69	EC₅₀	3.86 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NCI-H69 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H69 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H889	EC₅₀	0.015 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NCI-H889 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H889 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NOMO-1	EC₅₀	>5 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human NOMO-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NOMO-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
OCI-AML2	EC₅₀	0.1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human OCI-AML2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human OCI-AML2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
OCI-AML-3	EC₅₀	>5 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human OCI-AML-3 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human OCI-AML-3 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
OCI-AML-3	EC₅₀	6.8 μM Compound: ABT-199	Induction of apoptosis in human OCI-AML-3 cells measured after 48 hrs by FITC-Annexin V/PS staining based Induction of apoptosis in human OCI-AML-3 cells measured after 48 hrs by FITC-Annexin V/PS staining based	[PMID: 33197310]
OCI-AML-5	EC₅₀	0.11 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human OCI-AML5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human OCI-AML5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
Pfeiffer	IC₅₀	6.26 μM Compound: 7; ABT199	Antiproliferative activity against human Pfeiffer cells expressing high BCL-2/BFL-1 assessed as cell viability measured after 72 hrs by Cell Counting Kit-8 assay Antiproliferative activity against human Pfeiffer cells expressing high BCL-2/BFL-1 assessed as cell viability measured after 72 hrs by Cell Counting Kit-8 assay	[PMID: 38913996]
RPMI-8226	IC₅₀	2.7 μM Compound: ABT-199	Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 30594434]
RS4-11	EC₅₀	3 nM Compound: ABT-199	Induction of apoptosis in human RS4-11 cells Induction of apoptosis in human RS4-11 cells	[PMID: 32563811]
RS4-11	EC₅₀	8 nM Compound: 23	Antiproliferative activity against human RS4:11 cells in presence of 10% human serum Antiproliferative activity against human RS4:11 cells in presence of 10% human serum	[PMID: 28926247]
RS4-11	IC₅₀	0.0043 μM Compound: ABT-199	Cytotoxicity against human RS4-11 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Cytotoxicity against human RS4-11 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34228434]
RS4-11	IC₅₀	0.006 μM Compound: ABT-199; 1	Antiproliferative activity against human RS4:11 cells after 72 hrs by MTS assay Antiproliferative activity against human RS4:11 cells after 72 hrs by MTS assay	[PMID: 30278333]
RS4-11	IC₅₀	0.33 μM Compound: ABT-199	Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29453135]
RS4-11	IC₅₀	1.5 nM Compound: ABT-199	Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability	[PMID: 29407973]
RS4-11	IC₅₀	1.8 nM Compound: 6; ABT-199	Antiproliferative activity against human RS4-11 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human RS4-11 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34536651]
RS4-11	IC₅₀	110 nM Compound: 1c; ABT-199	Inhibition of cell growth in human RS4-11 cells harboring Bcl-2 G101V mutant incubated for 2 days by CellTiter-Glo luminescent cell viability assay Inhibition of cell growth in human RS4-11 cells harboring Bcl-2 G101V mutant incubated for 2 days by CellTiter-Glo luminescent cell viability assay	[PMID: 38695063]
RS4-11	IC₅₀	4.3 nM Compound: 1c; ABT-199	Inhibition of cell growth in human RS4-11 cells incubated for 2 days by CellTiter-Glo luminescent cell viability assay Inhibition of cell growth in human RS4-11 cells incubated for 2 days by CellTiter-Glo luminescent cell viability assay	[PMID: 38695063]
SET-2	EC₅₀	3.33 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human SET2 harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human SET2 harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
SIG-M5	EC₅₀	0.1 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human SIG-M5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human SIG-M5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
SKM-1	EC₅₀	2.53 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human SKM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human SKM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
THP-1	EC₅₀	0.82 μM Compound: ABT-199, GDC-0199	Antiproliferative activity against human THP-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human THP-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
Toledo	IC₅₀	0.011 μM Compound: ABT-199; 1	Antiproliferative activity against human Toledo cells after 72 hrs by MTS assay Antiproliferative activity against human Toledo cells after 72 hrs by MTS assay	[PMID: 30278333]
U-266	IC₅₀	94 μM Compound: ABT-199	Growth inhibition of human U266 cells after 72 hrs by MTT assay Growth inhibition of human U266 cells after 72 hrs by MTT assay	[PMID: 30594434]

In Vitro

Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC₅₀=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC₅₀=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC₅₀=3 nM) but is much less effective against BCL-XL-BCL-XS (EC₅₀=2.2 μM) or MCL-1-NOXA complexes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGI_max) of 47% (P<0.001) and tumor growth delay (TGD) of 26% (P<0.05)^[1].
Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days results in a significant reduction of leukemic burden^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1257044-40-8
Appearance Solid
Molecular Weight 868.44
Formula C₄₅H₅₀ClN₇O₇S
Color Light yellow to yellow
SMILES

O=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)CC4)C=C3OC7=CN=C(NC=C8)C8=C7
Synonyms

ABT-199; GDC-0199; RG7601
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (246)

All Cell Proliferation/Viability AssayWBIPBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nature

Dynamic antigen expression and cytotoxic T cell resistance in HIV reservoir clones. [Abstract]

2026 May;653(8115):850-860. PMID: 41735521
Nature

R-loop-derived cytoplasmic RNA-DNA hybrids activate an immune response. [Abstract]

2023 Jan;613(7942):187-194. PMID: 36544021
Nature

Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance. [Abstract]

2021 Mar;591(7850):477-481. PMID: 33627873
Cancer Cell

Stromal lipid species dictate melanoma metastasis and tropism. [Abstract]

2025 Apr 22:S1535-6108(25)00138-2. PMID: 40280124
Cancer Cell

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. [Abstract]

2024 Apr 8;42(4):552-567.e6. PMID: 38593781

Venetoclax purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Apr 8;42(4):552-567.e6. [Abstract]

Venetoclax (100 nM; 12-24 h). Western blot of the phosphorylation level of S6K1 upon the treatment of pegaspargase, venetoclax, or combination in both Nalm6 and 697 cells.
Cancer Cell

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. [Abstract]

2020 Dec 14;38(6):872-890.e6. PMID: 33217342

Venetoclax purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Dec 14;38(6):872-890.e6. [Abstract]

Cell viability of parental and venetoclax-resistant Molm-13 cells treated with MIK665 and +/− 1.3 μM venetoclax at 72 h.
Cancer Cell

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia. [Abstract]

2018 Aug 13;34(2):271-285.e7. PMID: 30107177
Cancer Cell

Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. [Abstract]

2017 Oct 9;32(4):490-505.e10. PMID: 29017059

Venetoclax purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2017 Oct 9;32(4):490-505.e10. [Abstract]

Immunoblot for BAX, BCL-2, BCL-XL, and MCL-1 from immunoprecipitates of BAX from OCI-AML3 cells treated with Venetoclax (1.25 μM), BTSA1 (1.25 μM), or in combination after 2.5 hr, and western blot detection for BAX, BCL-2, BCL-XL, and MCL-1.
Cell

Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. [Abstract]

2022 Apr 28;185(9):1521-1538.e18. PMID: 35447071
Mol Cancer

Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway. [Abstract]

2024 Oct 31;23(1):243. PMID: 39478582

Venetoclax purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Oct 31;23(1):243. [Abstract]

Venetoclax (10-160 μM; 12-72 h) combined with Cisplatin (2 μg/mL; 24-72 h) and Hydroxychloroquine (12.5-50 μM; 12-72 h) significantly inhibits the growth of H446/cDDP cells.
Mol Cancer

Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia. [Abstract]

2024 Sep 20;23(1):204. PMID: 39304903

Venetoclax purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Sep 20;23(1):204. [Abstract]

Venetoclax (0.1 µM; 24-96 h) significantly inhibits the proliferation of EG cells derived from FL (fetal liver) and CB (cord blood), and demonstrated enhanced inhibitory effects when combined with Trametinib (0.1 µM; 24-96 h).
Nat Cancer

Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. [Abstract]

2024 Jul;5(7):1082-1101. PMID: 38816660

Venetoclax purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2024 Jul;5(7):1082-1101. [Abstract]

Growth inhibition curves (left panel), IC50 values, and AUCs (right panel) of OCI-AML2 cells treated with DMSO or 500nM ARM165 in combination with increasing doses (10-10000 nM）of either venetoclax, S63845, WEHI-539 and A-1331852. Error bars represent mean ± SD of three biological replicates composed of seven technical repeats after three days of seeding.
Nat Immunol

Control of nutrient uptake by IRF4 orchestrates innate immune memory. [Abstract]

2023 Oct;24(10):1685-1697. PMID: 37697097
Nat Biomed Eng

Profiling protein-protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemia. [Abstract]

2024 Nov;8(11):1379-1395. PMID: 39025942
Blood

Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia. [Abstract]

2024 Aug 16:blood.2023023644. PMID: 39158067
Blood

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. [Abstract]

2021 Nov 18;138(20):1966-1979. PMID: 34132782
Blood

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. [Abstract]

2019 Jan 3;133(1):70-80. PMID: 30322870
Cell Stem Cell

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. [Abstract]

2026 Jun 4;33(6):982-999.e8. PMID: 42102807
Nat Cell Biol

Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor. [Abstract]

2017 Oct;19(10):1226-1236. PMID: 28945232

Venetoclax purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2017 Oct;19(10):1226-1236. [Abstract]

ABT-199 inhibits various forms of oncogenic GLI activation.
Cancer Res

Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. [Abstract]

2024 Nov 4;84(21):3629-3639. PMID: 39137400
Cancer Res

A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. [Abstract]

2022 Jun 6;82(11):2110-2123. PMID: 35405009
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia. [Abstract]

2025 Nov 21;16(1):10263. PMID: 41271691
Nat Commun

Attenuated growth factor signaling during cell death initiation sensitizes membranes towards peroxidation. [Abstract]

2025 Feb 25;16(1):1774. PMID: 40000627
Nat Commun

Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice. [Abstract]

2024 Jul 22;15(1):6162. PMID: 39039076
Nat Commun

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. [Abstract]

2023 Sep 19;14(1):5709. PMID: 37726279
Nat Commun

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics. [Abstract]

2022 Oct 2;13(1):5789. PMID: 36184661
Nat Commun

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry. [Abstract]

2021 Jun 23;12(1):3907. PMID: 34162861
Cell Death Differ

DR5/WDR12 balances p65 stability promoting sunitinib resistance in renal cell carcinoma. [Abstract]

2026 Mar 23. PMID: 41872532
Cell Death Differ

Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state. [Abstract]

2025 May;32(5):855-865. PMID: 39706991
Cell Death Differ

BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. [Abstract]

2020 Mar;27(3):999-1007. PMID: 31332296
Hemasphere

A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia. [Abstract]

2025 Jul 7;9(7):e70170. PMID: 40625531
Adv Sci (Weinh)

Beyond CD30: Dual-Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides. [Abstract]

2026 Feb 28:e17353. PMID: 41762706
Adv Sci (Weinh)

Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. [Abstract]

2025 Oct 23:e11573. PMID: 41126722
Interdiscip Med

2025 Sep 1;3(5):e70053.
J Clin Invest

BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. [Abstract]

2020 May 1;130(5):2542-2559. PMID: 32027622
Leukemia

Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma. [Abstract]

2025 Jul 30. PMID: 40739330
Leukemia

Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities. [Abstract]

2025 Jan;39(1):211-221. PMID: 39438587
Leukemia

Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition. [Abstract]

2024 Sep;38(9):1894-1905. PMID: 38997434
Leukemia

BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia. [Abstract]

2024 Jan;38(1):136-148. PMID: 37945692
Leukemia

An MDM2 degrader for treatment of acute leukemias. [Abstract]

2023 Feb;37(2):370-378. PMID: 36309559
Theranostics

GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. [Abstract]

2024 Jun 1;14(9):3470-3485. PMID: 38948063
Theranostics

Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression. [Abstract]

2022 Jul 18;12(12):5537-5550. PMID: 35910796
Nucleic Acids Res

Establishing artificial gene connections through RNA displacement-assembly-controlled CRISPR/Cas9 function. [Abstract]

2023 Aug 11;51(14):7691-7703. PMID: 37395400
Nucleic Acids Res

Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. [Abstract]

2020 Dec 16;48(22):12727-12745. PMID: 33245769

Venetoclax purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2020 Dec 16;48(22):12727-12745. [Abstract]

Co-immunoprecipitation assay and western blot showing immunoprecipitated Bcl-2, immunoblotted COX5A and IgG control lane. Input showing S70pBcl2, Bcl-2, COX5A, β-actin of Jurkat cells following treatment with venetoclax (2µM) for 24 hours.
J Exp Clin Cancer Res

Tetrahydrobenzimidazole TMQ0153 targets OPA1 and restores drug sensitivity in AML via ROS-induced mitochondrial metabolic reprogramming. [Abstract]

2025 Apr 7;44(1):114. PMID: 40197337
J Exp Clin Cancer Res

Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia. [Abstract]

2024 Jun 22;43(1):176. PMID: 38909249
Blood Cancer J

Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. [Abstract]

2026 May 7;16(1):107. PMID: 42098067
Blood Cancer J

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). [Abstract]

2022 Jan 11;12(1):5. PMID: 35017466
Gut Microbes

Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. [Abstract]

2024 Jan-Dec;16(1):2333790. PMID: 38533566
Cell Rep Med

FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia. [Abstract]

2025 Sep 19:102365. PMID: 40975063
J Immunother Cancer

BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer. [Abstract]

2025 May 7;13(5):e010073. PMID: 40341023
Cell Rep Med

Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. [Abstract]

2024 May 16:101580. PMID: 38776913
Pharmacol Res

Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer. [Abstract]

2023 Jan:187:106628. PMID: 36566002
Clin Cancer Res

The novel immunocompetent Eµ-SOX11CCND1 mouse model phenotypically and molecularly resembles human mantle cell lymphoma. [Abstract]

2025 Aug 26. PMID: 40857109
Clin Cancer Res

Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth. [Abstract]

2022 Jun 1;28(11):2409-2424. PMID: 35344040
Cell Mol Biol Lett

ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation. [Abstract]

2022 Mar 8;27(1):23. PMID: 35260073
Clin Cancer Res

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma. [Abstract]

2019 Jul 15;25(14):4455-4465. PMID: 31004002
Cancer Lett

FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia. [Abstract]

2024 Jun 28:592:216933. PMID: 38705564
Cancer Lett

High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma. [Abstract]

2023 Feb 1:554:216028. PMID: 36462556
Cell Death Dis

Radiation induces senescence in lymphatic endothelial cells (LECs) and murine tail lymphedema tissue, contributing to lymphedema progression. [Abstract]

2026 Jun 10. PMID: 42270600
Cell Death Dis

Inhibition of RNA polymerase II-activating CDK9 and CDK12/13, but not of cell cycle relevant CDKs, induces apoptosis by downregulating the short-lived Bcl-2 proteins Mcl1 and Bfl1/A1. [Abstract]

2026 May 27;17(1):512. PMID: 42204137
Cell Death Dis

2026 Apr 10;17(1):388.
Cell Death Dis

Repurposing BCL2 inhibitors: Venetoclax protects against acinar cell necrosis in acute pancreatitis by promoting apoptosis. [Abstract]

2025 Jul 27;16(1):566. PMID: 40715042
Cell Death Dis

Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]

2025 Mar 12;16(1):170. PMID: 40075071
Cell Death Dis

Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer. [Abstract]

2025 Mar 20;16(1):194. PMID: 40113795
Cell Death Dis

CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator. [Abstract]

2024 Aug 27;15(8):627. PMID: 39191721
Cell Death Dis

BCL-XL regulates the timing of mitotic apoptosis independently of BCL2 and MCL1 compensation. [Abstract]

2024 Jan 3;15(1):2. PMID: 38172496
Cell Death Dis

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax. [Abstract]

2022 Oct 8;13(10):860. PMID: 36209148
Cell Death Dis

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. [Abstract]

2021 Jul 27;12(8):741. PMID: 34315868
Cell Death Dis

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. [Abstract]

2020 Sep 18;11(9):778. PMID: 32948748
Cell Commun Signal

Decursin induces FLT3-ITD acute myeloid leukemia cell apoptosis by increasing the expression of the ubiquitin-conjugase UBE2L6. [Abstract]

2025 Apr 2;23(1):162. PMID: 40176110
Int J Biol Macromol

Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity. [Abstract]

2026 Jun:369:152633. PMID: 42167430
Apoptosis

BACH2 ameliorates cell apoptosis and autophagy as a molecular switch of BCL-2/Beclin-1 complex in myocardial infarction. [Abstract]

2026 Mar 15;31(3):100. PMID: 41838190
Chemosphere

An integrated in vitro approach to identifying chemically induced oxidative stress and toxicity in mitochondria. [Abstract]

2024 Feb:349:140857. PMID: 38070616
NPJ Precis Oncol

Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is characterized by high inter- and intra-model heterogeneity. [Abstract]

2025 Dec 29. PMID: 41457105
NPJ Precis Oncol

Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study. [Abstract]

2025 Nov 21;9(1):373. PMID: 41272086
NPJ Precis Oncol

Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy. [Abstract]

2022 Dec 1;6(1):90. PMID: 36456699
Haematologica

Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. [Abstract]

2017 Apr;102(4):755-764. PMID: 28104700
Neoplasia

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis. [Abstract]

2022 Jul;29:100798. PMID: 35462114
J Transl Med

Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax. [Abstract]

2025 Aug 14;23(1):917. PMID: 40814067
J Transl Med

Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma. [Abstract]

2025 Jan 22;23(1):103. PMID: 39844299
J Transl Med

Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis. [Abstract]

2023 Sep 7;21(1):606. PMID: 37679782
Biomed Pharmacother

NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes. [Abstract]

2022 Oct:154:113546. PMID: 35988426
PLoS Biol

Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity. [Abstract]

2020 Mar 17;18(3):e3000648. PMID: 32182234
Blood Adv

BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma. [Abstract]

2025 Jul 2:bloodadvances.2024015322. PMID: 40601898
Blood Adv

CBFA2T3::GLIS2 Pediatric Acute Megakaryoblastic Leukemia is Sensitive to BCL-XL Inhibition by Navitoclax and DT2216. [Abstract]

2024 Jan 9;8(1):112-129. PMID: 37729615
Blood Adv

PRMT5 Inhibition Drives Therapeutic Vulnerability to Combination Treatment with BCL-2 Inhibition in Mantle Cell Lymphoma. [Abstract]

2023 Oct 24;7(20):6211-6224. PMID: 37327122
Blood Adv

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. [Abstract]

2019 Dec 23;3(24):4202-4214. PMID: 31856269
Cell Death Discov

Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors. [Abstract]

2025 Feb 18;11(1):65. PMID: 39966387
Cell Death Discov

Dual role of PID1 in regulating apoptosis induced by distinct anticancer-agents through AKT/Raf-1-dependent pathway in hepatocellular carcinoma. [Abstract]

2023 Apr 28;9(1):139. PMID: 37117198
Cell Death Discov

PGD2 displays distinct effects in diffuse large B-cell lymphoma depending on different concentrations. [Abstract]

2023 Feb 1;9(1):39. PMID: 36725845
Cell Death Discov

A novel BH3 mimetic Bcl-2 inhibitor promotes autophagic cell death and reduces in vivo Glioblastoma tumor growth. [Abstract]

2022 Oct 29;8(1):433. PMID: 36309485
Cell Rep

A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential. [Abstract]

2025 Nov 25;44(11):116496. PMID: 41166305
Cell Rep

Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma. [Abstract]

2024 May 8;43(5):114211. PMID: 38722741
Cell Rep

Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia. [Abstract]

2023 Jan 31;42(1):112027. PMID: 36848231
J Med Chem

Discovery of a Novel MNK Inhibitor (NSP-1047) with In Vivo Anti-acute Myeloid Leukemia Activity. [Abstract]

2025 Aug 14;68(15):15617-15635. PMID: 40702697
Clin Transl Med

IRF4 contributes to chemoresistance in IGH::BCL2-positive diffuse large B-cell lymphomas by mediating BCL2-induced SOX9 expression. [Abstract]

2025 May;15(5):e70336. PMID: 40356256
Br J Cancer

Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma. [Abstract]

2017 Jun 6;116(12):1572-1584. PMID: 28494471
Mol Metab

Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells. [Abstract]

2026 Jun 17:110:102402. PMID: 42309255
Antioxidants (Basel)

Sesamin Protects Against Polystyrene Microplastics-Induced Lung Injury via Attenuating Bcl2-Mediated Apoptosis. [Abstract]

2026 Feb 24;15(3):279. PMID: 41897426
Sci Signal

Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. [Abstract]

2021 Jun 8;14(686):eabc7405. PMID: 34103421
Oncogenesis

Myeloma mesenchymal stem cells' bioenergetics afford a novel selective therapeutic target. [Abstract]

2025 Apr 11;14(1):9. PMID: 40216736
Fundam Res

2026 Mar 25.
Ecotoxicol Environ Saf

PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]

2025 Nov 15:307:119433. PMID: 41273832
JCI Insight

OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma. [Abstract]

2024 Mar 14;9(8):e172565. PMID: 38483541
JCI Insight

MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus. [Abstract]

2022 May 10;e150363. PMID: 35536646
Cancer Cell Int

Venetoclax synergizes with Wnt/β-catenin inhibitor C-82 in acute myeloid leukemia by increasing the degradation of Mcl-1 protein. [Abstract]

2025 May 29;25(1):197. PMID: 40442688
Cancer Cell Int

GANT61 surmounts drug resistance of ADR by upregulating lysosome activities and reducing BCL2 expression in HL-60/ADR cells. [Abstract]

2024 Dec 26;24(1):430. PMID: 39726048
J Invest Dermatol

Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. [Abstract]

2022 Jul;142(7):1912-1922.e7. PMID: 34942200
Biochem Pharmacol

Senolytic elimination of therapy-induced senescent cells by ABT-263 improves chemotherapeutic efficacy in esophageal squamous cell carcinoma. [Abstract]

2025 Dec 19:245:117659. PMID: 41423036
Biochem Pharmacol

Insight into the structure, function and the tumor suppression effect of gasdermin E. [Abstract]

2024 Jun 7:116348. PMID: 38852642
Biochem Pharmacol

BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells. [Abstract]

2023 Sep:215:115738. PMID: 37562509
Biochem Pharmacol

Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells. [Abstract]

2023 May:211:115494. PMID: 36924905
Biochem Pharmacol

AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells. [Abstract]

2023 Mar:209:115442. PMID: 36720359
Biochem Pharmacol

Hydroquinone destabilizes BIM mRNA through upregulation of p62 in chronic myeloid leukemia cells. [Abstract]

2022 May;199:115017. PMID: 35346662
Biochem Pharmacol

EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells. [Abstract]

2021 Jan;183:114352. PMID: 33278351
Biochem Pharmacol

TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. [Abstract]

2021 Jul:189:114085. PMID: 32522594
Breast Cancer Res Treat

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. [Abstract]

2019 Feb;173(3):585-596. PMID: 30374681
Mol Cancer Ther

Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4/6 inhibitors in prostate cancer. [Abstract]

2025 Jul 2. PMID: 40601842
Pharmaceutics

Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure. [Abstract]

2023 Mar 22;15(3):1016. PMID: 36986876
Mol Cancer Ther

Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199. [Abstract]

2021 Dec;20(12):2483-2494. PMID: 34711645
J Enzyme Inhib Med Chem

Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]

2025 Dec;40(1):2501743. PMID: 40371698
Am J Respir Cell Mol Biol

2026 Mar 11.
Cells

2026 Jan 16;15(2):164.
Cells

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263. [Abstract]

2022 Jun 21;11(13):1992. PMID: 35805077
Commun Biol

Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. [Abstract]

2024 Oct 4;7(1):1257. PMID: 39362994
Commun Biol

A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. [Abstract]

2022 Nov 26;5(1):1295. PMID: 36435843
RNA

Histone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis. [Abstract]

2024 Mar 18;30(4):435-447. PMID: 38296629
Int J Mol Sci

Folate-Appended Hydroxypropyl-β-Cyclodextrin Induces Autophagic Cell Death in Acute Myeloid Leukemia Cells. [Abstract]

2023 Nov 24;24(23):16720. PMID: 38069042
Int J Mol Sci

Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment. [Abstract]

2023 Aug 23;24(17):13082. PMID: 37685889
Pharmaceuticals (Basel)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. [Abstract]

2021 Jul 30;14(8):749. PMID: 34451846
Eur J Pharmacol

Quizartinib-induced resistance drives clonal emergence of MV4-11 cells with molecular alterations enabling multidrug antileukemic escape. [Abstract]

2026 May 10:1023:178877. PMID: 41997407
Int Immunopharmacol

Granulocyte colony-stimulating factor mediates bone loss via the activation of IL-1β/JNK signaling pathway in murine Staphylococcus aureus-induced osteomyelitis. [Abstract]

2024 Aug 19:141:112959. PMID: 39163688
Eur J Pharmacol

Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage. [Abstract]

2019 Jul 15:855:252-261. PMID: 31085238
Int J Cancer

Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer. [Abstract]

2018 Aug 1;143(3):645-656. PMID: 29488214
Cancer Biol Ther

Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL). [Abstract]

2025 Dec 31;26(1):2581831. PMID: 41220107
Cancer Biol Ther

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia. [Abstract]

2025 Dec;26(1):2457777. PMID: 39862423
Mol Oncol

Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially-dependent on MCL-1 and in plasma cells from patients. [Abstract]

2023 Dec;17(12):2507-2525. PMID: 37704591
Cancers (Basel)

CHRNB4-Mediated Neuroactive Signaling Rewiring Drives Adaptive Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia. [Abstract]

2026 Apr 8;18(8):1187. PMID: 42073514
Cancers (Basel)

DNMT3B Controls Enhancer-Linked Chromatin and Cell Cycle Networks in Acute Myeloid Leukemia. [Abstract]

2026 Feb 24;18(5):723. PMID: 41827658
Cancers (Basel)

Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma. [Abstract]

2023 Jan 13;15(2):510. PMID: 36672458
Clin Epigenetics

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression. [Abstract]

2022 Jul 7;14(1):84. PMID: 35799216
Cancers

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. [Abstract]

2020 Aug 5;12(8):2182. PMID: 32764384
J Ovarian Res

Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. [Abstract]

2016 Apr 14;9(1):25. PMID: 27080533
Transl Oncol

Inhibition of platin-induced BCL2 increase overcomes chemoresistance in squamous cell carcinoma of the head and neck through resensitization to cell death. [Abstract]

2025 Mar:53:102308. PMID: 39970625
iScience

Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity. [Abstract]

2024 Apr 9;27(5):109693. PMID: 38689642
J Cell Physiol

NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. [Abstract]

2021 Nov;236(11):7356-7375. PMID: 33982799
ACS Med Chem Lett

High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma. [Abstract]

2015 Jun 22;6(8):948-52. PMID: 26288699
Sci Rep

A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas. [Abstract]

2026 Jun 8. PMID: 42259859
J Biotechnol

FRET two-hybrid assay-based target drug screening in living cells. [Abstract]

2025 Nov 12:410:1-9. PMID: 41238124
Oncol Rep

Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro. [Abstract]

2022 Apr;47(4):66. PMID: 35103292
Anal Bioanal Chem

Dispersive solid-phase extraction as sample pretreatment for determination of chemotherapeutic agents revumenib and venetoclax by HPLC-DAD. [Abstract]

2025 Jul;417(16):3703-3714. PMID: 40323377
Br J Haematol

Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway. [Abstract]

2023 Sep;202(5):971-984. PMID: 37409755
Cell Signal

PERK-eIF2alpha-mediated translational inhibition of MCL-1 contributes to potential 2-deoxy-D-glucose and BAD mimetic combinatorial cancer therapy. [Abstract]

2025 Dec 19:139:112333. PMID: 41423011
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
PLoS Genet

Myeloid Targeted Human MLL-ENL and MLL-AF9 Induces cdk9 and bcl2 Expression in Zebrafish Embryos. [Abstract]

2024 Jun 3;20(6):e1011308. PMID: 38829886
Dis Colon Rectum

Combinatorial Inhibition of Complement Factor D and BCL2 for Early-Onset Colorectal Cancer. [Abstract]

2024 Jul 1;67(7):940-950. PMID: 38479005
Mol Cell Biochem

Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. [Abstract]

2020 Sep;472(1-2):187-198. PMID: 32567031
Med Oncol

Targeted delivery of venetoclax-encapsulated human heavy chain ferritin nanoparticles in acute myeloid leukemia. [Abstract]

2026 Feb 5;43(3):132. PMID: 41642506
Biology (Basel)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2. [Abstract]

2023 Oct 16;12(10):1337. PMID: 37887047
Exp Cell Res

Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax. [Abstract]

2022 May 11;417(2):113192. PMID: 35568072
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
J Invest Surg

Rapamycin Inhibits Nf-ΚB Activation by Autophagy to Reduce Catabolism in Human Chondrocytes. [Abstract]

2020 Oct;33(9):861-873. PMID: 30945580
ChemMedChem

Advancing Accurate Quantification of Protein-Ligand Interactions: Differential Scanning Calorimetry as a Precision Screening Tool Using BCL-2 as a Model System. [Abstract]

2026 Mar 13;21(5):e202500744. PMID: 41774457
Cell Cycle

Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia. [Abstract]

2025 Dec 15:1-19. PMID: 41399259
BMC Cancer

Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo. [Abstract]

2024 Nov 4;24(1):1350. PMID: 39497108
BMC Cancer

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement. [Abstract]

2024 Jun 25;24(1):761. PMID: 38918775
Toxicol Appl Pharmacol

CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells. [Abstract]

2022 Jan 15:435:115847. PMID: 34963561
J Immunol

Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells. [Abstract]

2021 Nov 15;207(10):2598-2607. PMID: 34607937
Toxicol Appl Pharmacol

Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells. [Abstract]

2020 Jan 15;387:114857. PMID: 31837377
Cancer Res Commun

p97 Inhibition Synergistically Enhances Hypomethylating Therapy through Targeting of PLK1 in Acute Myeloid Leukemia. [Abstract]

2026 Jun 1;6(6):1509-1521. PMID: 42248070
Cancer Res Commun

Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. [Abstract]

2023 Feb 21;3(2):297-308. PMID: 36860654
Mol Carcinog

Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL-2. [Abstract]

2025 Jul 24. PMID: 40705959
Naunyn Schmiedebergs Arch Pharmacol

PIM1-mediated signalling as a therapeutic target in breast cancer: repurposing venetoclax for targeted inhibition. [Abstract]

2026 May 30. PMID: 42217041
J Endocr Soc

Humanin Treatment Protects Against Venetoclax-Induced Bone Growth Retardation in Ex Vivo Cultured Rat Bones. [Abstract]

2024 Jan 25;8(3):bvae009. PMID: 38328478
Cancer Med

HOXA10 induces BCL2 expression, inhibits apoptosis, and promotes cell proliferation in gastric cancer. [Abstract]

2019 Sep;8(12):5651-5661. PMID: 31364281
Discov Oncol

Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells. [Abstract]

2022 Feb 3;13(1):9. PMID: 35201512
J Cell Biochem

Mcl-1 is a Gatekeeper Molecule to Regulate the Crosstalk Between Ferroptotic Agent-Induced ER Stress and TRAIL-Induced Apoptosis. [Abstract]

2025 Jan;126(1):e30681. PMID: 39853862
Technol Cancer Res Treat

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response. [Abstract]

2023 Jan-Dec:22:15330338231208608. PMID: 37880950
Genes (Basel)

The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia. [Abstract]

2023 Oct 8;14(10):1916. PMID: 37895265
J Chromatogr B Analyt Technol Biomed Life Sci

Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. [Abstract]

2020 Sep 1;1152:122176. PMID: 32534260
PLoS One

Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. [Abstract]

2025 Jan 21;20(1):e0308747. PMID: 39836700
PLoS One

Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway. [Abstract]

2024 Jul 25;19(7):e0307662. PMID: 39052583
Oncologie

2024 Jul 16.
PeerJ

Identification of Aloperine as an anti-apoptotic Bcl2 protein inhibitor in glioma cells. [Abstract]

2019 Sep 3;7:e7652. PMID: 31534865
Gene

Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells. [Abstract]

2019 Mar 10:688:1-6. PMID: 30415007
Leuk Lymphoma

IFN-γ enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway. [Abstract]

2023 Jan;64(1):71-78. PMID: 36222521
Biochem Biophys Res Commun

BAK plays a key role in A-1331852-induced apoptosis in senescent chondrocytes. [Abstract]

2022 Jun 18;609:93-99. PMID: 35421634
Biochem Biophys Rep

Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. [Abstract]

2020 Apr 22;22:100756. PMID: 32346617
Biochem Biophys Res Commun

ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma. [Abstract]

2018 Sep 10;503(3):1214-1220. PMID: 30017199

Venetoclax purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2018 Sep 10;503(3):1214-1220. [Abstract]

Bcl-2 family protein expression is assessed by western blotting in CNE-2 and 5-8F cells after treatment with ABT-199 for 48 h.
Bioanalysis

LC-MS/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction. [Abstract]

2022 Jan;14(2):75-86. PMID: 34841894
Transl Cancer Res

Knockdown of MEF2D inhibits the development and progression of B-cell acute lymphoblastic leukemia. [Abstract]

2023 Feb 28;12(2):287-300. PMID: 36915581
Translational Cancer Research

Vol 6, No 4. 2017.

Venetoclax purchased from MedChemExpress. Usage Cited in: Translational Cancer Research. Vol 6, No 4. 2017.

ABT-199 regulates p53/p21 signaling to induce G2/M phase arrest in DOHH2 cells. Representative blots of CDK1/cdc2, cyclin B1, p21 and p53 in DOHH2 cells treated with ABT-199 at 0.1 and 1 μM for 24 h. β-actin is used as the internal control.
Braz J Med Biol Res

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells. [Abstract]

2024 Oct 7:57:e13278. PMID: 39383379
STAR Protoc

Protocol for detecting lysosome quantity and membrane permeability in acute myeloid leukemia cell lines. [Abstract]

2024 Sep 12;5(3):103309. PMID: 39269898
STAR Protoc

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models. [Abstract]

2021 May 12;2(2):100461. PMID: 34027474
bioRxiv

2026 Jun 25.
Res Sq

2026 Jun 15.
University of North Carolina at Chapel Hill

2026.
bioRxiv

2026 May 1.
Blood Neoplasia

From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models. [Abstract]

2026 Apr 9;3(3):100230. PMID: 42294111
bioRxiv

Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention. [Abstract]

2026 Apr 15:2026.04.13.718209. PMID: 42039381
chemRxiv

2026 Apr 6.
bioRxiv

2026 Mar 28.
bioRxiv

2026 Mar 20.
bioRxiv

2026 Mar 21.
bioRxiv

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma. [Abstract]

2026 Feb 20:2026.02.19.706849. PMID: 41756844
Charles University

2026.
Res Sq

Rewired Neuroactive Ligand-Receptor Signaling Confers Adaptive Resistance to BCL-2 Inhibition in AML. [Abstract]

2026 Jan 12:rs.3.rs-8427312. PMID: 41646400
bioRxiv

PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockade. [Abstract]

2026 Jan 23:2026.01.20.700677. PMID: 41648616
Skin Health Dis

2026 Jan 19.
bioRxiv

CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteins. [Abstract]

2025 Dec 26:2025.12.24.696284. PMID: 41509496
Res Sq

Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax. [Abstract]

2025 Nov 19:rs.3.rs-7682325. PMID: 41333384
bioRxiv

2025 Sep 16.
University of Sao Paulo

2025.
bioRxiv

2025 Jul 17.
bioRxiv

2025 July 16.
Seoul National University

2025.
Res Sq

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression. [Abstract]

2025 Mar 31:rs.3.rs-6249480. PMID: 40235506
bioRxiv

Autophagy inhibition induces AML cell death and enhances the efficacy of chemotherapy under hypoxia. [Abstract]

2024 Nov 26:2024.11.24.625107. PMID: 39651164
bioRxiv

PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. [Abstract]

2024 Nov 6:2024.11.04.621884. PMID: 39574568
EJC Paediatr Oncol

2024 Jun 3.
McGill University

2023 Dec.
Université de Lausanne

2024 Feb 7.
Research Square Preprint

2023 Dec 6.
bioRxiv

2023 Oct 10.
bioRxiv

2023 Oct 1.
bioRxiv

2023 Aug 5.
University of Gothenburg

2023 Jun 27.
bioRxiv

2023 May 12.
Patent

US20230145200A1.
Patent

US20230113802A1.
bioRxiv

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML. [Abstract]

2023 Mar 15:2023.03.13.531236. PMID: 36993676
Research Square Print

2023 Jan 9th,
Patent

US20220347180A1.
Research Square Preprint

2022 Jul.
Research Square Preprint

2022 May.
Oxid Med Cell Longev

TNF- α Induces Neutrophil Apoptosis Delay and Promotes Intestinal Ischemia-Reperfusion-Induced Lung Injury through Activating JNK/FoxO3a Pathway. [Abstract]

2021 Dec 29:2021:8302831. PMID: 35003520
University of Colorado

2020 Dec.
Universidad De Salamanca

2020 Nov.
Research Square Preprint

A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry. [Abstract]

2020 Aug 14;rs.3.rs-48659. PMID: 32818215
University of Michigan

2020 May.
bioRxiv

2020 Feb.
Moscow State University

2019 Jul.
Charles University

2019 Jun.

Solvent & Solubility

In Vitro:

DMSO : 77.5 mg/mL (89.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : < 1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1515 mL

5.7575 mL

11.5149 mL

5 mM

0.2303 mL

1.1515 mL

2.3030 mL

10 mM

0.1151 mL

0.5757 mL

1.1515 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (2.88 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 45% PEG300 5% Tween-80 50% Saline

Solubility: 10 mg/mL (11.51 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 10 mg/mL (11.51 mM); Suspended solution; Need ultrasonic

Protocol 3

Add each solvent one by one: 17% Solutol HS-15 in Saline

Solubility: 20 mg/mL (23.03 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

RS4;11 cells are seeded at 50,000 per well in 96-well plates and treated with compounds diluted in half-log steps starting at 1 μM and ending at 0.00005 μM. All other leukemia and lymphoma cell lines are seeded at 15,000-20,000 cells per well in the appropriate medium and incubated with Venetoclax or Navitoclax for 48 h. Effects on proliferation are determined using Cell TiterGlo reagent. EC₅₀ values are determined by nonlinear regression analysis of the concentration-response data. Mouse FL5.12-BCL-2 and FL5.12-BCL-XL cells are propagated and assessed. Bak^-/- Bax^-/- double knockout mouse embryonic fibroblasts are seeded into 96-well microtiter plates at 5,000 cells per well in DMEM supplemented with 10% FBS. Venetoclax (ABT-199) in the same culture medium is added in half-log dilutions starting at 5 μM. The cells are then incubated at 37°C (5% CO₂) for 48 h, and the effects on proliferation are determined using Cell TiterGlo reagent^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
Nonobese diabetic/severe combined immunodeficient γ (NSG) mice are injected at 6 weeks of age in the tail vein with 150 µL phosphate-buffered saline containing 5×10⁶ luciferase-labeled LOUCY cells. At regular time points, the bioluminescence is measured using the IVIS Lumina II imaging system. At 6 weeks, the cells are engrafted and the mice are randomly divided into 2 groups (with an equal number of males and females in both groups), and the treatment is started on day 0. Mice are treated with Venetoclax (ABT-199) 100 mg/kg body weight or with vehicle via oral gavage for 4 consecutive days. At days 0, 2, and 4 the bioluminescene is measured.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. [Content Brief]

[2]. Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47. [Content Brief]

[3]. Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102(4):755-764. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1515 mL	5.7575 mL	11.5149 mL	28.7873 mL
	5 mM	0.2303 mL	1.1515 mL	2.3030 mL	5.7575 mL
	10 mM	0.1151 mL	0.5757 mL	1.1515 mL	2.8787 mL
	15 mM	0.0768 mL	0.3838 mL	0.7677 mL	1.9192 mL
	20 mM	0.0576 mL	0.2879 mL	0.5757 mL	1.4394 mL
	25 mM	0.0461 mL	0.2303 mL	0.4606 mL	1.1515 mL
	30 mM	0.0384 mL	0.1919 mL	0.3838 mL	0.9596 mL
	40 mM	0.0288 mL	0.1439 mL	0.2879 mL	0.7197 mL
	50 mM	0.0230 mL	0.1151 mL	0.2303 mL	0.5757 mL
	60 mM	0.0192 mL	0.0960 mL	0.1919 mL	0.4798 mL
	80 mM	0.0144 mL	0.0720 mL	0.1439 mL	0.3598 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Venetoclax

Apoptosis Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Peptidomimetic Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Chemical Probe Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Mitochondria-Targeted Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

Protein-protein Interaction Inhibitor Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Venetoclax

All Bcl-2 Family Isoforms

Biological Activity

Chemical Information

Publications (246)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Venetoclax Related Classifications

Cat. No.: HY-15531